News
fr | en
26 December 2017
Signature Licence OP2 Liryc

The company OP2 signs an exclusive license with the IHU Liryc, the University Hospital of Bordeaux, the University of Bordeaux and Aquitaine Science Transfert to develop a new treatment against myocardial infarction. Find the press release here.